Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 15172772)

1.

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.

Lancet. 2004 May 29;363(9423):1751-6.

PMID:
15172772
3.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

4.
5.

Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.

McGettigan P, Han P, Jones L, Whitaker D, Henry D.

Br J Clin Pharmacol. 2008 Jun;65(6):927-34. doi: 10.1111/j.1365-2125.2008.03121.x. Epub 2008 Apr 1.

7.
8.

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

Arch Intern Med. 2003 Feb 24;163(4):481-6.

PMID:
12588209
9.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

10.

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

Arch Intern Med. 2005 May 9;165(9):978-84.

PMID:
15883235
11.
12.
13.

Factors associated with celecoxib and rofecoxib utilization.

Rawson NS, Nourjah P, Grosser SC, Graham DJ.

Ann Pharmacother. 2005 Apr;39(4):597-602. Epub 2005 Mar 8.

PMID:
15755796
14.

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.

PMID:
17086567
15.
17.

Are rofecoxib and celecoxib safer NSAIDS?

[No authors listed]

Drug Ther Bull. 2000 Nov;38(11):81-6. Review.

PMID:
11138599
18.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

Ann Intern Med. 2005 Feb 1;142(3):157-64.

PMID:
15684203
19.

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.

Drug Saf. 2006;29(7):621-32.

PMID:
16808554
20.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk